Quan Thai, NP
Adult Health · Stanford, CANPI 1700029105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 30.7% of the total. 2025 is the largest year on record at $594, 2.5 times the $236 reported in 2021.
Across 53 payments — averaging $32.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$533
- AbbVie$182
- AstraZeneca$174
- Merck$124
- GSK$78
- Johnson & Johnson$77
- plus $566 from 18 others
What the payments were for
- Food & beverage$1,63995%
- Education$955%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $533 |
| AbbVie | 4 | $182 |
| AstraZeneca | 7 | $174 |
| Merck | 4 | $124 |
| GSK | 3 | $78 |
| Johnson & Johnson | 2 | $77 |
| Myriad Genetic Laboratories, Inc. | 1 | $68 |
| Gilead(2 entities) | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Novartis | 2 | $49 |
| Genentech USA, Inc. | 1 | $35 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $27 |
| Amgen | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $23 |
| Sanofi | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $19 |
| EMD Serono, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$128
How this compares
$1,734 in reported general payments places this provider in the 80th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other adult health in Stanford
- Dana DolceStanford$5K
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.